Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today ...

In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, expectations were $-1.07. Operator: Good day, and thank you for standing by.

Duke University and Duke-NUS Medical School are proud to announce the recipients of their latest Research Collaboration Pilot Project grants, totalling more than S$1 million.

Operator: Good day, and welcome to the Aethlon Medical Third Quarter Fiscal 2025 Earnings and Corporate Update Call. All ...

Ginger is known for its soothing effects on the stomach, and can effectively relieve nausea. It may also play a role in ...

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They ...

Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...

Background Cancer, a major global health challenge, not only threatens lives but also imposes severe financial burdens, known ...

publish an annual summary of regulatory activities Pump ... pumps (including basic demographic data) the results of clinical research conducted into the human factors associated with newly ...

Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...